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Abstract. Methods of identifying chronic wounds that will 
heal in a timely, coordinated fashion and those that will not, 
together with novel therapeutic strategies, are vital for progres-
sion in the field of wound healing. Interleukin (IL)‑7 has been 
associated with various biological and pathological processes. 
The present study explored the potential role of IL‑7 in wound 
healing. IL‑7 expression levels were examined in a clinical 
cohort of chronic wounds using reverse transcription-quanti-
tative polymerase chain reaction and immunohistochemical 
staining analysis. The impact of recombinant human IL‑7 
(rhIL‑7) on the growth and migrational rates of HaCaT kerati-
nocyte cells was subsequently examined using in vitro growth 
and electric cell‑substrate impedance sensing functional 
assays. The mRNA expression levels of IL‑7 were increased 
in the healed chronic wound tissue samples, compared with 
non-healed chronic wound tissue samples, although the differ-
ence was not statistically significant. Similarly, immunohisto-
chemical analysis revealed a greater staining intensity of IL‑7 
in the healed chronic wound tissue sections compared with 
the non‑healed tissue sections. Treatment with rhIL‑7 did not 
affect HaCaT cell growth rates, but was shown to enhance cell 
migration, an effect that could be further enhanced through the 
addition of inhibitors of neuronal Wiskott‑Aldrich syndrome 
protein and protein kinase B. The data of the present study 
suggest that the expression levels of IL‑7 may be increased in 
healing chronic wounds, and thus IL‑7 may have a role in this 
process, potentially through its effects on the cellular migra-
tion of keratinocytes.
Introduction
Wound healing is a complex and dynamic process that is 
essential for tissue homeostasis. In normal adult wound 
healing, disruption to skin integrity triggers a series of coordi-
nated events typically classified into three overlapping phases: 
The inflammatory phase entails recruitment of inflammatory 
cells into the wound; the proliferative phase involves the 
formation of granulation tissue and re-epithelialisation; and 
during the remodelling phase, the wound contracts and the 
scar matures (1). Chronic wounds may be defined as those that 
fail to progress through the reparative processes required to 
restore tissue integrity within three months (2). This inability 
to heal is associated with cellular and molecular abnormalities 
within the wound bed and often involves chronic inflamma-
tion (3). Chronic wounds represent a significant burden to 
the UK National Health Service, with an estimated cost of 
>£1 billion per year (4). One of the major challenges for clini-
cians is recognising which wounds will heal and which will 
become chronic; therefore, methods for early diagnosis of the 
non-healing wound are important for earlier and more aggres-
sive intervention.
In 1988, a novel growth factor for precursor B cells was 
identified and designated lymphopoietin‑1 (5). Now more 
commonly known as interleukin (IL)‑7, its functional signifi-
cance and therapeutic potential continue to be investigated. As 
a pleiotropic cytokine, IL‑7 is involved in early B and T cell 
development (5-10), growth, maintenance and differentiation of 
thymocytes (11-14) and peripheral T‑cell homeostasis (15-17). 
IL‑7 expression has been detected in numerous types of tissue, 
including bone marrow (5), thymus gland (9,12), liver, kidney, 
spleen (8), intestine (18,19) and skin (6,19,20).
The IL‑7 receptor (IL‑7R) complex is a heterodimer of 
transmembrane proteins, the IL‑7 specific α chain (also known 
as CD127) and the common γ chain (CD132) (21,22). Neither 
component is unique to IL‑7 signalling, with the α chain also 
being utilised by thymic stromal lymphopoietin (23,24) and 
the common γ chain by other members of the interleukin 
family, including IL‑2, IL‑4, IL‑9 and IL‑15 (25-28). Although 
it is predominantly expressed by cells of the lymphoid lineage, 
IL‑7R has also been detected in human endothelial cell lines (29) 
and several cancer cell lines, including lung, central nervous 
system, renal, colon, breast and skin cancer, as well haemato-
logical malignancies (30). It also exists in a soluble form that 
is capable of binding IL‑7 in solution (21). IL‑7R activation by 
IL‑7 binding leads to dose‑dependent phosphorylation of Janus 
kinase (JAK)‑1 and JAK‑3 and subsequent phosphorylation of 
signal transducer and activator of transcription 5, which then 
translocates to the nucleus to induce gene transcription (31,32), 
as reviewed by Mazzucchelli and Durum (33). IL‑7 has also 
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been demonstrated to activate the phosphatidylinositol 3 
kinase (PI3K)/protein kinase B (Akt) signalling pathway in 
murine and human thymocytes which is known to influence 
cell survival (32,34,35); however, the exact nature of this 
signalling pathway is not fully understood.
Although its role in immunological development has 
been known for some time, studies with IL‑7 transgenic mice 
revealed its potential to act as an oncogene in vivo and promote 
the malignant transformation of B and T cells (36). IL‑7 has 
been demonstrated to affect cell growth and survival in certain 
haematological malignancies, including acute lymphoblastic 
leukaemia (37-39), cutaneous T cell lymphoma (20,40,41), 
Hodgkin's disease (42), acute myeloid leukaemia (43) and 
chronic lymphocytic leukaemia (39,43,44). IL‑7 mRNA 
has also been identified in numerous solid organ tumours, 
including Warthin's tumour of the parotid gland (45), head and 
neck squamous cell carcinomas (46), renal cell carcinoma (47), 
oesophageal carcinoma (48), colorectal carcinoma (49) and 
breast carcinoma (19). The exact role of IL‑7 in these tumours 
is not fully understood, however it is thought to affect lympho-
cytes (49); for instance, in cutaneous T‑cell lymphoma, IL‑7 
has been shown to support the growth of malignant T‑cells 
in the skin (21). Increased IL‑7 expression in breast cancer is 
associated with a higher tumour grade and poorer prognostic 
outcome (19). This may be due to the effects of aberrant IL‑7 
expression on the development, growth and differentiation of 
breast cancer (19), the ability of IL‑7 to act as a potent growth 
factor for breast cancer and endothelial cells (50) and/or the 
ability of IL‑7 to stimulate lymphangiogenesis in breast cancer 
cells in vitro and in a mouse model (51,52). These findings 
are concordant with analyses conducted on non-small cell lung 
cancer (NSCLC), in which tumours with high IL‑7 expression 
were more advanced and more likely to have metastasised 
to lymph nodes, possibly due to stimulation of lymphan-
giogenesis (53). Postoperative survival rates were shorter 
in patients with higher levels of IL‑7/IL‑7R expression (54). 
Furthermore, the expression levels of IL‑7 have been reported 
to correlate with tumour stage and the presence of lymph 
node metastases (54). In vitro studies have demonstrated that 
IL‑7 stimulates lung cancer cell proliferation and increases 
cyclin D1 mRNA and protein expression, higher levels of 
which correlate with reduced survival rates in patients with 
NSCLC (55).
During the study of IL‑7 within the fields of haematology and 
immunology, it was noted that murine and human normal kera-
tinocytes express IL‑7 mRNA and protein in vitro (6,20,56). 
It appears that one function of IL‑7 in skin is to promote 
the survival and growth of epidermal T‑cells (56,57). These 
results prompted further investigation of the role of IL‑7 in 
inflammatory cutaneous disease, and its involvement has been 
suggested in atopic dermatitis (6), bullous pemphigoid (58) and 
cutaneous T‑cell lymphoma (20). To the best of our knowl-
edge, no reports have been published regarding a correlation 
between IL‑7 and wound healing. Parallels have been made 
between the pathophysiological parameters observed in cancer 
biology and wound healing (59,60). Given the involvement of 
IL‑7 in inflammation and immune responses, its role in tumour 
development and progression and its expression by human 
keratinocytes, the present study investigated the effect of IL‑7 
on wound healing.
Materials and methods
Wound tissue cohort. Information regarding the wound tissue 
cohort and collection has been previously described (61). 
Briefly, the tissue cohort consisted of 71 chronic venous 
leg ulcer wound edge biopsies. The tissue samples were 
collected from patients attending the University of Wales 
wound healing clinic, following ethical approval by the 
South East Wales Research Ethics Committee (reference 
no. 09/WSE02/59). Informed written consent was provided 
by all patients. Samples were obtained from 71 patients 
between 2010 and 2013, 43% of whom were male and 57% 
were female. The mean age of these patients was 72.2 years, 
with a sample range of 34-99 years old. Over a 12 week 
follow‑up of the subjects, 20 chronic wounds displayed 
substantial healing following conventional compression 
therapy and these samples were thus defined as ‘healing’ 
chronic wounds. The remaining chronic wounds that 
remained static or were enlarged over the 12‑week period 
of conventional therapy were termed ‘non-healing’ chronic 
wounds for the purpose of this study. Biopsies were initially 
stored at ‑80˚C prior to immersion in liquid nitrogen. The 
tissue biopsies were sectioned using a CM1950 cryostat 
(Leica Microsystems Ltd., Milton Keynes, UK) at a size of 
7 µm for immunohistochemical analysis and 20 µm for use 
in RNA extraction and generation of cDNA for reverse tran-
scription‑quantitative polymerase chain reaction (RT‑qPCR) 
analysis, where multiple tissue sections were combined and 
homogenised using a hand held homogeniser (Cole‑Parmer 
Instrument Co., Ltd., London, UK) in ice‑cold total RNA 
isolation reagent (TRI) reagent® (Sigma‑Aldrich Co., Ltd., 
Irvine, UK).
Reagents, cell lines and culture conditions. The HaCaT human 
keratinocyte cell line was purchased from the German Cancer 
Research Institute (Heidelberg, Germany). The cells were 
grown and maintained at 37˚C, 5% CO2 and 95% humidity in 
Dulbecco's modified Eagle's medium (Sigma‑Aldrich Co., Ltd.) 
supplemented with 10% foetal calf serum (Sigma‑Aldrich Co., 
Ltd.) and 100X antibiotic antimycotic solution (Sigma‑Aldrich 
Co., Ltd.; final concentration 50,000 units penicillin, 50 mg 
streptomycin and 125 µg amphotericin B per 500 ml). 
Recombinant human IL‑7 (rhIL‑7) was purchased from R&D 
Systems (Abingdon, UK). The neuronal Wiskott‑Aldrich 
syndrome protein (N-WASp) inhibitor Wiskostatin and the Akt 
inhibitor were purchased from Merck Millipore (Calbiochem; 
Watford, UK).
RNA extraction and reverse transcription. Total RNA was 
extracted from the homogenised sections of wound tissue 
and human keratinocytes using TRI reagent as described in 
the manufacturer's protocol (Sigma‑Aldrich Co., Ltd.). Once 
extracted, the RNA was quantified using a spectrophotometer 
(WPA UV 1101; Biotech Photometer, Cambridge, UK) and 
RNA quantity was standardised to 250 ng prior to reverse 
transcription using an iScript cDNA synthesis kit according 
to the manufacturer's instructions (Bio‑Rad Laboratories Ltd., 
Hemel Hempstead, UK). Subsequently, cDNA was diluted 
1:16 with nuclease‑free water (Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) and used for RT‑qPCR.
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Immunohistochemical staining. Frozen wound tissue sections 
were fixed in dried acetone (Thermo Fisher Scientific, Inc.) for 
15 min, air dried for 15 min and then hydrated in Tris‑buffered 
saline (TBS). The tissue sections were incubated in wash buffer 
containing 10% horse serum (Sigma‑Aldrich Co., Ltd.) for 1 h 
prior to incubation with monoclonal mouse anti‑IL‑7 primary 
antibody (cat. no. MAB207; R&D Systems) diluted at a 1:100 
concentration (2 µg/ml final concentration) for 1 h at room 
temperature. Subsequently, the tissue sections were washed 
four times in TBS buffer prior to identification of primary 
antibody binding using a Vectastain Elite ABC (Universal) 
avidin‑biotin peroxidase kit in accordance with the manufac-
turer's protocol (Vector Laboratories, Ltd., Peterborough, UK). 
Visualisation of the staining intensity was obtained through 
the addition of 3,3'‑diaminobenzidine to the tissue sections. 
Finally, tissue sections were counterstained with haematoxylin 
(Vector Laboratories, Ltd.), washed thoroughly in tap water 
and subjected to dehydration through a graded series (50, 70, 
90, 100, 100%) of absolute ethanol (Thermo Fisher Scientific, 
Inc.), prior to being cleared in xylene and mounted in DPX 
mounting medium (Merck Millipore). Staining intensity and 
localisation were visualised under a Leica DM1000 LED 
microscope (Leica Microsystems Ltd.). Negative controls 
were prepared using only the secondary universal antibody 
contained within the Vectastain Elite ABC (Universal) kit, in 
accordance with the manufacturer's protocol.
RT‑qPCR. IL‑7 expression levels were examined within 
the wound tissue cohort using RT-qPCR as previously 
described (61,62). Briefly, the primer pairs were designed 
incorporating a complementary sequence (termed the 
Z sequence) to the Amplifluor uniprimer probe (InterGen, 
New York, NY, USA) into the reverse primer. RT‑qPCR was 
undertaken using an IQ5 system (Bio‑Rad Laboratories, Ltd.) 
and transcript copy numbers were calculated based on the 
quantification of a defined internal standard run on the same 
plate. Sample/standard cDNA was added to iQ supermix 
(Bio‑Rad Laboratories Ltd.), target specific forward primer 
(10 pM), reverse primer containing the Z sequence (1 pM) and 
the Amplifluor uniprimer probe (10 pM). The reaction condi-
tions were as follows: 15 min at 95˚C followed by 80 cycles of 
95˚C for 15 sec, 55˚C for 60 sec and 72˚C for 20 sec. Sample 
transcript number was subsequently normalised based on 
sample total expression levels of the GAPDH housekeeping 
gene. Full primer details are presented in Table I.
In vitro growth assay. An in vitro cell growth assay was used 
to examine the impact of IL‑7 on HaCaT cell growth. HaCaT 
cells were seeded at a density of 3x103 cells/well into triplicate 
96‑well plates. Plates were treated, where required, with the 
indicated concentration of rhIL‑7 (0, 1, 10 and 100 ng/ml) and 
incubated overnight for 3 or 5 days. At each incubation point the 
appropriate 96‑well plate was fixed in 4% formaldehyde (v/v) 
and stained with 0.5% (w/v) crystal violet (Sigma‑Aldrich Co., 
Ltd.). Plates were subsequently treated with 10% acetic acid 
(v/v) and placed in an ELx800 spectrophotometer plate reader 
(Bio‑Tek Instruments Inc., Winooski, VT, USA).
Electric cell‑substrate impedance sensing (ECIS) detection of 
cell migration. Cell migration was detected using an ECIS Zθ 
system (Applied Biophysics Inc., Troy, NY, USA) as described 
previously (63). Briefly, cells were added to 96-well electrode 
arrays (96W1E) in identical numbers (80,000 cells/well) 
and allowed to form a fully confluent monolayer. Following 
confluence, the cells were wounded through the application of 
6 V for 30 sec/well, generating a consistently sized ‘wound’ 
in the monolayer. The change in resistance was measured in 
each well as the cells migrated back to recolonise the elec-
trode. This process was completed in the presence of varying 
concentrations of rhIL‑7 (0, 1, 10 and 100 ng/ml) and the rate 
of change of resistance was taken as an indication of cellular 
migration. Subsequently, 20 ng/ml of rhIL‑7 was used in 
conjunction with a range of small molecule inhibitors to deter-
mine potential interactions between these signalling pathways 
on IL‑7‑regulated migration.
Statistical analysis. The SigmaPlot 11 statistical software 
package (Systat Software Inc., London, UK) was used to 
identify statistically significant differences between experi-
mental groups. The data were analysed using parametric two 
sample, two-tailed t‑test or analysis of variance (ANOVA), 
or non‑parametric Mann‑Whitney or ANOVA on RANKS 
depending on normality. All in vitro assays were repeated a 
minimum of three times. Data is presented as mean ± standard 
deviation or median ± interquartile range. P<0.05 was consid-
ered to indicate a statistically significant result.
Results
IL‑7 expression levels in healing and non‑healing chronic 
wounds. RT-qPCR was used to compare the mRNA levels 
of IL‑7 expression in the healing and non‑healing wounds 
(Fig. 1). IL‑7 expression levels were higher in healing chronic 
wounds (median expression, 0.196) compared with non‑healing 
chronic wounds (median expression, 0.00469), although this 
difference was not statistically significant (P=0.229). 
Immunohistochemical analysis was performed on 
26 representative chronic wound tissue samples. A total of 
Table I. Primers used in the present study. 
Primer Forward (5'‑3') Reverse (3'‑5')
IL‑7 ATTGTGATATTGAAGGTAAAGATG ACTGAACCTGACCGTACAGCACGGAATAAA
GAPDH  AAGGTCATCCATGACAACTT ACTGAACCTGACCGTACAGCCATCCACAGTCTTCTG
ACTGAACCTGACCGTACA denotes the Z sequence. IL, interleukin.
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13 tissue samples were defined as non‑healing (wound size 
had increased or remained the same), and the remaining 
13 as healing (wounds had either completely healed or there 
was a decrease in size). In line with the RT‑qPCR findings, 
IL‑7 expression was generally enhanced in healing wound 
tissue and the majority of healing wounds (8/13) showed cyto-
plasmic IL‑7 expression in all the layers of the epidermis. By 
contrast, the majority of the non‑healing wounds did not show 
IL‑7 expression (9/13), and in cases where faint staining was 
observed, it was localised in the basal layer (Fig. 2).
IL‑7 enhances keratinocyte migration in vitro. To determine 
the effect of IL‑7 on keratinocyte migration in vitro, HaCaT 
cells were treated with various concentrations of rhIL‑7 
and cell migration was analysed using the ECIS system. 
Following electrical wounding, HaCaT cells treated with 
rhIL‑7 migrated at a faster rate compared with untreated cells 
(Fig. 3A) and there appeared to be a concentration‑dependent 
gradient, with the maximum effect observed following 
treatment with 100 ng/ml rhIL‑7. To further investigate this 
effect, cell migration was examined in the presence of IL‑7 
and numerous small molecule signalling pathway inhibi-
tors. Concordant with the original observations, treatment 
of HaCaT cells with IL‑7 (20 ng/ml) induced an increase in 
cell migration rates compared with the untreated controls. 
However, marked effects on cell migration were observed 
when rhIL‑7 was combined with an Akt inhibitor (Fig. 3B) or 
N‑WASp inhibitor (Fig. 3C). In both cases, the combination 
of rhIL‑7 with the inhibitor induced an evident increase in 
cellular migration rate.
IL‑7 does not affect keratinocyte growth in vitro. To determine 
the effect of IL‑7 on keratinocyte growth, HaCaT cells were 
treated with various concentrations of rhIL‑7 and cell growth 
was analysed over a 3‑day or 5‑day incubation period. No 
difference in cell growth was observed between the untreated 
HaCaT controls and the cells treated with various concentra-
tions of rhIL‑7 at day 3 or 5, and there were no statistically 
significant differences observed between the groups at days 3 
or 5 (P>0.05; Fig. 4).
Discussion
Wound healing is a complex process that requires interac-
tion between numerous cytokines and growth factors (1). A 
greater understanding of these factors and interactions may 
provide an insight into possible treatments of chronic wounds. 
Therefore, the present study investigated the presence of 
IL‑7 in healing and non‑healing wounds, and its effect on 
keratinocytes in vitro.
Figure 2. Immunohistochemical staining analysis of IL‑7 expression in 
clinical tissue samples. Staining profiles demonstrated an increase in 
IL‑7 expression in chronic‑healing tissue sections compared with chronic 
non‑healing tissue sections. Representative images are shown at x40, x100, 
x200 and x400 magnifications. Negative controls are representative of tissue 
sections undergoing staining with only secondary antibody. IL‑7, inter-
leukin‑7.
Figure 1. Reverse transcription‑quantitative polymerase chain reaction 
analysis of IL‑7 expression levels in clinical samples. Median IL‑7 expres-
sion levels were increased in healing chronic wounds compared with 
non-healing chronic wounds, although no significant differences were 
observed. Descriptive data is presented in the table. IL‑7, interleukin‑7; IQR, 
interquartile range.
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IL‑7 is a pleomorphic cytokine expressed in normal 
human keratinocytes (6), where it has been previously shown 
to support epidermal T‑cell growth and survival (56,57). It has 
an important role in immunological development, including 
involvement in early B‑ and T‑cell development (5-10) and 
peripheral T‑cell homeostasis (15-17). IL‑7 may also act as 
an oncogene, stimulating malignant transformation, and cell 
growth and survival in haematological cancers (36-43).
The results of the present study demonstrated that IL‑7 
expression was higher in healing chronic wounds compared 
with non-healing chronic wounds, although the difference was 
not statistically significant. This was supported by immuno-
histochemical analysis, which also demonstrated that IL‑7 
expression was enhanced in healing chronic wounds, being 
expressed in all layers of the epidermis. To investigate the 
potential underlying causes for this, the effects of rhIL‑7 on 
human keratinocytes were analysed in vitro. Although rhIL‑7 
treatment led to faster keratinocyte migration, it did not affect 
the cell growth. Therefore, if IL‑7 is affecting wound healing, 
it appears that the mechanism underlying its effects may occur 
via enhanced keratinocyte migration. Given that previous 
studies have demonstrated the role of IL‑7 as a growth factor 
for epidermal T‑cell growth and survival (56,57), it is possible 
that IL‑7 may be involved in the inflammatory phase of wound 
healing. However, a study of mRNA expression in human 
dermal wounds demonstrated that IL‑7 mRNA expression 
levels initially decreased then increased in the middle and late 
phases of wound healing (64). These results are concordant 
with the data of the present study, which indicated that rhIL‑7 
enhanced keratinocyte migration, a process that occurs during 
re‑epithelialisation. IL‑7 was shown to be a growth factor for 
endothelial cells in breast cancer studies (51,52); therefore, it 
may influence neoangiogenesis and re‑vascularisation, another 
essential element of wound healing that occurs following the 
initial inflammatory phase. Since IL‑7 supports cancer cell 
proliferation and growth (20,50,54), it was initially hypoth-
esised that it may enhance keratinocyte growth in vitro. 
However, no significant impact of rhIL‑7 on HaCaT cell growth 
was observed following in vitro assays, despite the addition of 
high concentrations of rhIL‑7.
Akt is a serine/threonine kinase involved in numerous 
cellular signalling pathways. It is an important mediator of 
numerous functions initiated by growth factor receptors that 
activate PI3K (65). Akt is oncogenic and contributes to the 
malignant behaviour of cells, promoting cell survival, enhancing 
tumour cell invasion, and stimulating motility (66). IL‑7 has 
been shown to activate the PI3K/Akt signalling pathway, 
promoting the survival of certain immune and cancer 
cells (32,34,35,67). In order to evaluate the potential signal-
ling pathways involved in the pro‑migratory effect of rhIL‑7 
on HaCaT cells, two small inhibitors (Akt and N‑WASp) were 
used to target the possible downstream signalling pathways of 
IL‑7. Since previous studies suggested that Akt stimulates cell 
motility, a reasonable hypothesis appears to be that inhibiting 
Akt may negate the pro‑migratory effect of IL‑7. However, 
Figure 4. Cell growth rate analysis. No significant effects on growth 
potential were observed in the HaCaT keratinocyte cell line following the 
addition of rhIL‑7 at 1, 10 or 100 ng/ml concentrations. Data are presented as 
mean ± standard error. rhIL‑7, recombinant human interleukin‑7. 
Figure 3. Electric cell substrate impedance sensing analysis of cellular migra-
tion. (A) Following electrical wounding rhIL‑7 was demonstrated to have a 
dose‑dependant effect on cellular migration. (B) Addition of the Akt inhibitor 
or the (C) N‑WASp inhibitor wiskostatin in combination with rhIL‑7 sub-
stantially enhanced the pro‑migrational impact compared with rhIL‑7 alone. 
Representative images shown. rhIL‑7, recombinant human interleukin‑7; 
Akt, protein kinase B.
  A
  B
  C
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the opposite was shown, since a marked increase in cell 
migration was observed upon addition of the Akt inhibitor. A 
previous study demonstrated that IL‑24 inhibited keratinocyte 
migration in vitro via an Akt‑dependent signalling pathway, 
where addition of an Akt inhibitor reversed the inhibition of 
migration caused by IL‑24 (61). However, the results of the 
current study suggested that inhibition of Akt, through small 
molecular inhibitors, had a pro‑migratory effect on HaCaT 
cells when combined with rhIL‑7 treatment. The precise 
mechanism underlying this phenomenon is not fully known.
Wiskott‑Aldrich syndrome (WAS) is a primary immu-
nodeficiency disorder, in which lymphocytes exhibit 
cytoskeletal abnormalities and a reduced response to prolif-
erative stimuli (68). The WAS gene encodes a prolene‑rich 
protein, termed WASp. Neural WASp (N‑WASp) is a 65 kDa 
protein with a 50% homology to WASp that was first iden-
tified in the bovine brain (69). Unlike WASp, which is only 
expressed in haematopoietic cells, N‑WASp is ubiquitous (68). 
N‑WASp is required for stimulation of actin polymerization, a 
process necessary for cell movement and division (70). It has 
also been shown to stabilise intracellular adherens junctions, 
which maintain the endothelial barrier (71). The results of the 
present study demonstrated that inhibition of N‑WASp caused 
a marked increase in the cellular migration rate with the 
addition of rhIL‑7 in vitro. This suggested that N‑WASp may 
have been acting to prevent migration, possibly replicating its 
activity in endothelial cells.
In conclusion, as chronic wounds continue to pose a signif-
icant health problem, investigations to uncover the complex 
processes required for prompt wound healing are ongoing. 
The results of the present study demonstrated that IL‑7 may 
have a role in keratinocyte migration and may be differentially 
expressed between healing and non‑healing chronic wounds. 
Further studies are required to fully establish this association 
and the significance of IL‑7 in chronic wound healing and in 
the wound healing process as a whole, using different clinical 
cohorts with acute and chronic wound tissues. The data also 
suggested a potential association between IL‑7 and N‑WASp 
and Akt signalling, although additional investigation isre-
quired to fully understand this association and its significance 
to clinical wound healing.
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